On (b)(6) 2018, abaxis received a call from the customer lab stating that the device yielded unexpected high potassium results compared to a outside lab with the same draw.The patient was admitted prior to blood sample for pain, swelling, dehydration, and rhabdomyolysys, which is an indicator for high creatine kinase.The patient was being treated with an iv.Abaxis technical support informed the lab that the package insert states the k+ assay in the piccolo system is a coupled pyruvate kinase (pk) / lactate dehydrogenase (ldh) assay.Therefore, in cases of extreme muscle trauma or highly elevated levels of creatine kinase (ck), the piccolo may recover a falsely elevated potassium (k+) value.In such cases, unexpected high potassium recoveries need to be confirmed utilizing a different methodology.The lab understood and has not experienced any more unexpected high potassium results since.The call was closed and no further actions were required.This mdr is being submitted as a result of a three (3) year retrospective review of closed complaints abaxis performed as part of its commitment to correct the fda-483 observations received on august 22, 2019.
|